share_log

UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50

Benzinga Real-time News ·  Feb 2, 2023 08:44

UBS analyst John Sourbeer initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces Price Target of $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment